9d
Clinical Trials Arena on MSNNeurocrine Biosciences debuts new data for effectiveness of IngrezzaOf the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...
Hosted on MSN1mon
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales forceHe emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.
As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...
Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...
Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...
US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...
"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition ...
Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...
Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...
Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...
"The significant improvements observed in AIMS score and the high remission rates highlight the efficacy of INGREZZA, at even the lowest dose." The post-hoc analysis was conducted using data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results